AMAG - AMAG Pharmaceuticals, Inc.
| Previous Close | 24.75 |
| Open | 24.45 |
| Bid | 17.35 x 4000 |
| Ask | 27.00 x 3100 |
| Day's Range | 22.25 - 24.65 |
| 52 Week Range | 11.93 - 25.63 |
| Volume | 4,534,588 |
| Avg. Volume | 785,011 |
| Market Cap | 816.973M |
| Beta | 0.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire•3 days ago
California Cryobank And Cord Blood Registry To Be Combined By GI Partners To Create A Leading Life Sciences Platform
LOS ANGELES, June 15, 2018 /PRNewswire/ -- California Cryobank, the world's leading donor sperm and donor egg bank, announced today that it has signed a definitive agreement for GI Partners, a private equity investment firm, to acquire the company from leading healthcare investors Longitude Capital and NovaQuest Capital. In a separate transaction announced today, GI Partners has also entered into a definitive agreement with AMAG Pharmaceuticals, Inc. (AMAG) to acquire Cord Blood Registry (CBR), the world's largest stem cell collection and storage company.
- GlobeNewswire•3 days ago
AMAG Pharmaceuticals Announces Divestiture of Cord Blood Registry®
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has entered into a definitive agreement to divest Cord Blood Registry (CBR®) to GI Partners, a private equity investment firm, for $530 million in an all cash sale. “The divestiture of CBR is an important step as we execute on AMAG's strategic plan, which includes leveraging our proven expertise in drug development and commercialization to bring innovative products to patients with unmet medical needs,” said William Heiden, president and chief executive officer at AMAG.
- ACCESSWIRE•5 days ago
Initiating Free Research Reports on ArQule and Three Other Biotech Equities
In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.
- GlobeNewswire•6 days ago
AMAG Pharmaceuticals, Inc. and March of Dimes Announce Collaboration to Improve Health of Mothers and Babies
AMAG Pharmaceuticals, Inc. (AMAG) and March of Dimes today announced a strategic corporate partnership focused on a shared commitment to improve maternal health and birth outcomes, as well as to reduce health inequities. Through the partnership, AMAG will participate in the March of Dimes Prematurity Campaign Collaborative and support the expansion of the March of Dimes’ Supportive Pregnancy Care (SPC) model, an innovative group prenatal care program. “AMAG’s commitment to support the health of patients and families encompasses far more than the therapies we offer to help moms and babies.
- GlobeNewswire•14 days ago
AMAG Pharmaceuticals Announces FDA Acceptance of New Drug Application Filing for Bremelanotide
AMAG Pharmaceuticals, Inc. (AMAG) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bremelanotide, a first-in-class melanocortin 4 receptor agonist designed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The Prescription Drug User Fee Act (PDUFA) date for completion of FDA review of the bremelanotide NDA is March 23, 2019.
- GlobeNewswire•20 days ago
AMAG Pharmaceuticals to Present at Upcoming Investor Conference
AMAG Pharmaceuticals, Inc. (AMAG) today announced that management will participate in the Jefferies 2018 Healthcare Conference on Tuesday, June 5th at 3:30 p.m. ET. AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.
- GlobeNewswire•last month
AMAG Pharmaceuticals Commends CMS for Clarifying Part D Coverage of Treatments for Moderate to Severe Dyspareunia Due to Menopause
WALTHAM, Mass., May 09, 2018-- AMAG Pharmaceuticals, Inc. today commended the recent action taken by the Centers for Medicare and Medicaid Services to clarify statutory intent of section§ 1860 D-2 of the ...
- ACCESSWIRE•last month
Wired News – Auris Medical Reported Publication Related to AM-111 in Peer-Reviewed Scientific Journal Hearing Research
LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Auris Medical Holding AG (NASDAQ: EARS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EARS as the Company's latest news hit the wire. On May 04, 2018, the Switzerland-based biopharmaceutical Company announced that the article reviewing the mechanism of action, pharmacokinetics and therapeutic applications of AM-111, the Company's investigational treatment for acute inner ear hearing loss, was published in Hearing Research, one of the leading journals in the otorhinolaryngology field. The peer-reviewed article "Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)" was published.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals Announces First Quarter 2018 Financial Results and Raises Full Year Financial Guidance
Strong first quarter execution with two FDA approvals and submission of a new drug application. Conference call scheduled for 8:00 a.m. ET today. WALTHAM, Mass., May 03, 2018-- AMAG Pharmaceuticals, Inc. ...
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals Appoints J. Alan Butcher as Executive Vice President and Chief Business Officer
AMAG Pharmaceuticals, Inc. (AMAG) today announced the appointment of J. Alan Butcher as executive vice president and chief business officer effective immediately. In his role at AMAG, Mr. Butcher is responsible for leading the company’s overall business development efforts, with a focus on continuing to expand the portfolio with products that address unmet patient needs. Additionally, he oversees the company's alliance management team, and leads the corporate strategy function in close collaboration with Mr. Heiden, the senior leadership team, and the board of directors.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., April 27, 2018-- AMAG Pharmaceuticals, Inc. today announced that company management will participate in the following investor conferences:. Deutsche Bank Annual Health Care Conference ...
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 3, 2018 at 8:00 a.m. ET
WALTHAM, Mass., April 26, 2018-- AMAG Pharmaceuticals, Inc. today announced that its first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the U.S. financial markets open. ...
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within AMN Healthcare Services, Cass Information, William Lyon Homes, AMAG Pharmaceuticals, Intersect ENT, and First Financial — Discovering Underlying Factors of Influence
NEW YORK, April 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•3 months ago
AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
WALTHAM, Mass., March 26, 2018-- AMAG Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for bremelanotide, which AMAG in-licensed ...
- PR Newswire•3 months ago
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
CRANBURY, N.J., March 26, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, announced today that its exclusive North American licensee for bremelanotide, AMAG Pharmaceuticals, Inc. (AMAG), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. If approved, bremelanotide would become the first and only as desired pharmacologic option in the U.S. indicated for the treatment of HSDD in premenopausal women.
- ACCESSWIRE•4 months ago
AMAG Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 8:00 AM ...
- ACCESSWIRE•4 months ago
Blog Exposure - FDA Granted Approval to AMAG’s Makena(R) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-risk Women
LONDON, UK / ACCESSWIRE / February 20, 2018 / Active-Investors.com has just released a free research report on AMAG Pharma, Inc. (NASDAQ: AMAG) ("AMAG"). If you want access to this report all ...